J&J joins the com­bo line­up at Bris­tol-My­ers, where a new wag­on mas­ter runs on­col­o­gy R&D

J&J is tak­ing an im­muno-on­col­o­gy drug li­censed in from Aduro and match­ing it with Bris­tol-My­ers Squibb’s pi­o­neer­ing check­point drug Op­di­vo in the lat­est ex­am­ple of the tsuna­mi of I/O com­bo stud­ies tak­ing shape off the coast of the glob­al R&D in­dus­try. The move comes one day af­ter Bris­tol-My­ers $BMY tapped a vet­er­an play­er to take the head of its rapid­ly grow­ing on­col­o­gy de­vel­op­ment op­er­a­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER